MedTrace Logo

Myopia Control: a Comparison Study Between Atropine and MiSight

NCT05815784 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 348

Last updated 2024-11-19

No results posted yet for this study

Summary

This research project aims to provide additional knowledge of pharmacological and optical methods of myopia control and to gain a better understanding of the biometry of the pediatric eye, which contributes to the onset and progression of myopia. As a result, this study will improving our best practices for myopia control in pediatric patients.

Conditions

  • Myopia

Interventions

DRUG

Atropine

0.05% atropine. One drop per eye per day for 2 years.

DEVICE

MiSight contact lenses

Daily wear for 2 years.

Sponsors & Collaborators

  • Ann & Robert H Lurie Children's Hospital of Chicago

    lead OTHER

Principal Investigators

  • Magdalena Stec, OD · Ann & Robert H Lurie Children's Hospital of Chicago

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-02
Primary Completion
2026-03-13
Completion
2026-03-13
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05815784 on ClinicalTrials.gov